Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling

Nutrition and Diabetes

Volumn 6, Issue 12, 2016, Pages

  Pastel, E ^a   Joshi, S ^a   Knight, B ^a,b   Liversedge, N ^b   Ward, R ^a   Kos, K ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CD14 ANTIGEN; CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA SUBUNIT 1; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA SUBUNIT 1; COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA SUBUNIT 1; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; EXENDIN 4; FIBRONECTIN; GELATINASE B; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEPTIN; LYSOSYL OXIDASE; LYSOSYL OXIDASE LIKE 2; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CYTOKINE; INCRETIN; PEPTIDE; VENOM;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ARTICLE; ELECTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIPOGENESIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OMENTUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; AGED; AGONISTS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INFLAMMATION; METABOLISM; OBESITY;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; AGED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIN; EXTRACELLULAR MATRIX; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; INFLAMMATION; MIDDLE AGED; OVERWEIGHT; PEPTIDES; VENOMS;

EID: 85006018064     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2016.44     Document Type: Article

References (30)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
2. Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacother J Hum Pharmacol Drug Ther 2015; 35: 926-934
3. Alkhouli N, Mansfield J, Green E, Bell J, Knight B, Liversedge N, et al. The mechanical properties of human adipose tissues and their relationships to the structure and composition of the extracellular matrix. Am J Physiol Endocrinol Metab 2013; 305: E1427-E1435
4. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue : composition, distribution, and link with lipid metabolism and fat. Diabetes 2010; 59: 2817-2825
5. Clément K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657-1669
6. Vendrell J, El Bekay R, Peral B, García-Fuentes E, Megia A, Macias-Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 2011; 152: 4072-4079
7. Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D, et al. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol 2015; 110: 20
8. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-Amide an antagonist at the glucagon-like peptide 1-(7-36)-Amide receptor of insulin- secreting β-cells. J Biol Chem 1993; 268: 19650-19655
9. McCulloch LJ, Rawling TJ, Sjöholm K, Franck N, Dankel SN, Price EJ, et al. COL6A3 is regulated by leptin in human adipose tissue and reduced in obesity. Endocrinology 2015; 156: 134-146
10. Kos K, Wong S, Tan B, Gummesson A, Jernas M, Franck N, et al. Regulation of the fibrosis and angiogenesis promoter SPARC / osteonectin in human adipose tissue by weight. Diabetes 2009; 58: 1780-1788
11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
12. Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol Endocrinol Metab 2015; 309: E691-E714
13. Kim YM, Kim EC, Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 2011; 38: 145-149
14. Henegar C, Tordjman J, Achard V, Lacasa D, Cremer I, Guerre-Millo M, et al. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 2008; 9: R14
15. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to metabolic syndrome. Endocr Rev 2000; 21: 697-738
16. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-2326
17. Drolet R, Bélanger C, Fortier M, Huot C, Mailloux J, Légaré D, et al. Fat depotspecific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring) 2009; 17: 424-430
18. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33: 1734-1737
19. El Bekay R, Coín-Aragüez L, Fernández-García D, Oliva-Olivera W, Bernal-López R, Clemente-Postigo M, et al. Effects of GLP-1 on the differentiation and metabolism of human adipocytes. Br J Pharmacol 2016; 173: 1820-1834
20. Yang W-S, Lee W-J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C-L, et al. Weight reduction increases plasma levels of an adipose-derived anti inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819
21. Kim Chung LT, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009; 390: 613-618
22. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun 2012; 425: 304-308
23. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE, Peterson CA, et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 2011; 96: E1990-E1998
24. DeMarsilis AJ, Walji TA, Maedeker JA, Stoka KV, Kozel BA, Mecham RP, et al. Elastin insufficiency predisposes mice to impaired glucose metabolism. J Mol Genet Med 2014; 8: 1-16
25. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12
26. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012; 97: 198-207
27. Tanaka K, Masaki Y, Tanaka M, Miyazaki M, Enjoji M, Nakamuta M, et al. Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J Gastroenterol 2014; 20: 2653-2663
28. Vohl M, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res 2004; 12: 1217-1222
29. Ai G, Chen Z, Shan C, Che J, Hou Y, Cheng Y. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. Int J Pharm 2008; 353: 56-64
30. Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 2012; 55: 2456-2468